Annual EBITDA
-$67.52 M
-$32.32 M-91.83%
December 31, 2023
Summary
- As of February 21, 2025, SPRY annual EBITDA is -$67.52 million, with the most recent change of -$32.32 million (-91.83%) on December 31, 2023.
- During the last 3 years, SPRY annual EBITDA has fallen by -$67.06 million (-14483.15%).
- SPRY annual EBITDA is now -14483.15% below its all-time high of -$463.00 thousand, reached on December 1, 2020.
Performance
SPRY EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$21.75 M
-$6.41 M-41.77%
September 30, 2024
Summary
- As of February 21, 2025, SPRY quarterly EBITDA is -$21.75 million, with the most recent change of -$6.41 million (-41.77%) on September 30, 2024.
- Over the past year, SPRY quarterly EBITDA has dropped by -$6.41 million (-41.77%).
- SPRY quarterly EBITDA is now -242.81% below its all-time high of -$6.34 million, reached on June 30, 2022.
Performance
SPRY Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$60.51 M
-$3.77 M-6.64%
September 30, 2024
Summary
- As of February 21, 2025, SPRY TTM EBITDA is -$60.51 million, with the most recent change of -$3.77 million (-6.64%) on September 30, 2024.
- Over the past year, SPRY TTM EBITDA has dropped by -$3.77 million (-6.64%).
- SPRY TTM EBITDA is now -758.36% below its all-time high of -$7.05 million, reached on March 31, 2022.
Performance
SPRY TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
SPRY EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -91.8% | -41.8% | -6.6% |
| 3 y3 years | -10000.0% | -41.8% | -6.6% |
| 5 y5 years | -10000.0% | -41.8% | -6.6% |
SPRY EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -250.9% | at low | -242.8% | at low | -758.4% | +16.5% |
| 5 y | 5-year | <-9999.0% | at low | -242.8% | at low | -758.4% | +16.5% |
| alltime | all time | <-9999.0% | at low | -242.8% | at low | -758.4% | +16.5% |
ARS Pharmaceuticals EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$21.75 M(+41.8%) | -$60.51 M(+6.6%) |
| Jun 2024 | - | -$15.34 M(+16.3%) | -$56.74 M(-8.5%) |
| Mar 2024 | - | -$13.19 M(+29.0%) | -$62.00 M(-8.2%) |
| Dec 2023 | -$67.52 M | -$10.23 M(-43.1%) | -$67.52 M(-6.8%) |
| Sep 2023 | - | -$17.98 M(-12.7%) | -$72.44 M(+18.6%) |
| Jun 2023 | - | -$20.60 M(+10.1%) | -$61.08 M(+30.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2023 | - | -$18.71 M(+23.6%) | -$46.82 M(+33.2%) |
| Dec 2022 | -$35.20 M(+82.9%) | -$15.14 M(+128.7%) | -$35.16 M(+75.7%) |
| Sep 2022 | - | -$6.62 M(+4.4%) | -$20.02 M(+49.5%) |
| Jun 2022 | - | -$6.34 M(-10.0%) | -$13.39 M(+90.0%) |
| Mar 2022 | - | -$7.05 M | -$7.05 M |
| Dec 2021 | -$19.24 M(+4055.7%) | - | - |
| Dec 2020 | -$463.00 K | - | - |
FAQ
- What is ARS Pharmaceuticals annual EBITDA?
- What is the all time high annual EBITDA for ARS Pharmaceuticals?
- What is ARS Pharmaceuticals annual EBITDA year-on-year change?
- What is ARS Pharmaceuticals quarterly EBITDA?
- What is the all time high quarterly EBITDA for ARS Pharmaceuticals?
- What is ARS Pharmaceuticals quarterly EBITDA year-on-year change?
- What is ARS Pharmaceuticals TTM EBITDA?
- What is the all time high TTM EBITDA for ARS Pharmaceuticals?
- What is ARS Pharmaceuticals TTM EBITDA year-on-year change?
What is ARS Pharmaceuticals annual EBITDA?
The current annual EBITDA of SPRY is -$67.52 M
What is the all time high annual EBITDA for ARS Pharmaceuticals?
ARS Pharmaceuticals all-time high annual EBITDA is -$463.00 K
What is ARS Pharmaceuticals annual EBITDA year-on-year change?
Over the past year, SPRY annual EBITDA has changed by -$32.32 M (-91.83%)
What is ARS Pharmaceuticals quarterly EBITDA?
The current quarterly EBITDA of SPRY is -$21.75 M
What is the all time high quarterly EBITDA for ARS Pharmaceuticals?
ARS Pharmaceuticals all-time high quarterly EBITDA is -$6.34 M
What is ARS Pharmaceuticals quarterly EBITDA year-on-year change?
Over the past year, SPRY quarterly EBITDA has changed by -$6.41 M (-41.77%)
What is ARS Pharmaceuticals TTM EBITDA?
The current TTM EBITDA of SPRY is -$60.51 M
What is the all time high TTM EBITDA for ARS Pharmaceuticals?
ARS Pharmaceuticals all-time high TTM EBITDA is -$7.05 M
What is ARS Pharmaceuticals TTM EBITDA year-on-year change?
Over the past year, SPRY TTM EBITDA has changed by -$3.77 M (-6.64%)